Coherus BioSciences Inc. officially announced its name change to Coherus Oncology, Inc., effective May 30, 2025. This rebranding aligns the company's identity with its exclusive focus on proprietary innovative immuno-oncology medicines.
The name change marks the culmination of a strategic transformation that saw the company divest its biosimilar businesses to concentrate entirely on cancer therapeutics. This pivot aims to leverage Coherus's expertise and pipeline in combination therapies to extend cancer patient survival.
As Coherus Oncology, the company will continue to advance its pipeline, including LOQTORZI, casdozokitug, and CHS-114, in pursuit of new treatment paradigms in the high-stakes field of oncology. This strategic clarity is expected to enhance its position in the competitive immuno-oncology landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.